An increase in attention-deficit/hyperactivity disorder (ADHD) diagnoses since 2020, along with shortages in prescription stimulants and an increase in overdose deaths from stimulants, has triggered alarm within the public sector, regulatory agencies, and health care systems. Stimulants are classified as Schedule II drugs by the Drug Enforcement Administration due to the potential for misuse and physiological and psychological dependence. Despite concerns, stimulants are effective first-line…
